Navigation Links
Leaders in the Study of Allosteric Modulation to Discuss Latest Research at Allosteric and Orthosteric Modulator Congress
Date:11/4/2009

Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.

Minneapolis, Minnesota (PRWEB) November 4, 2009 -- Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.

Our speakers will discuss key developments in the field, including the challenges facing researchers, the opportunities for pharma and recent successes in the field.

Allosteric modulators are on the cutting edge of small molecule drug discovery, and therefore, are generating a great deal of excitement among researchers. This potential stems from their ability to offer greater selectivity and better modulatory control at disease mediating receptors. Since orthosteric modulators need to compete with natural ligands, they require higher doses, raising safety issues. Allosteric modulators do not compete and may therefore be effective at lower, safer doses.

Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress will highlight many key developments in the field. Conference attendees will come away with a better understanding of the following topics:

- Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders
- Dualsteric GPCR testing
- Allosteric modulation of GPCRs and transporters for the treatment of depression
- Structure-function approaches to understanding allosteric modulation of GPCRs
- Allosteric modulation of purine receptors
- Discovery of small molecule GPCR modulators
- Muscarinic receptors/GPCRs in endocrine and central nervous systems
- Morpheeins as a new pathway for allosteric drug discovery
- Allosteric proteins and the concept of allosteric modulators

Speakers at this year’s congress include:

- P. Jeffrey Conn, Ph.D., Director, Vanderbilt Program in Drug Discovery, Lee E. Limbird Professor of Pharmacology, Vanderbilt University Medical Center
- Patrick M. Sexton, Ph.D., Professor of Pharmacology, Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences & Department of Pharmacology, Monash University
- Jean-Pierre Changeux, Ph.D., Professor, Institut Pasteur
- Charlotte Keywood, MD, Chief Medical Officer, Addex Pharmaceuticals
- Connie Sanchez, Ph.D., Vice President Neuroscience, Lundbeck Research USA
- Prof. Dr. Klaus Mohr, Chairman, Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn
Kenneth A. Jacobson, Ph.D., Acting Chief, Laboratory of Bioorganic Chemistry, National Institutes of Health
Robert Lütjens, Ph.D., Head of Core Biology, Addex Pharmaceuticals
Marlene A. Jacobson, Ph.D., Senior Investigator, Merck Research Labs
Jurgen Wess, Ph.D., Chief, Molecular Signaling Section, National Institutes of Health, NIDDK

For more information about this conference, please visit www.allostericmodulatorcongress.com/ or call 1-312-244-3703.

# # #

Read the full story at http://www.prweb.com/releases/2009/11/prweb3154864.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Yakima Health Care Leader Tapped for Leadership Post at National Association
2. Tennessee Faith Leaders Call on Reps. Gordon & Blackburn to Co-sponsor Legislation to Protect Kids from Tobacco
3. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
4. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
5. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
6. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
7. Hooper Holmes Launches Health & Wellness Division at 2007 Disease Management Leadership Forum and Integrated Care Summit
8. CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans
9. Blue Care Network of Michigan Earns National Leadership Award for Chronic Disease Management
10. Schooner Healthcare Services, LLC Announces New Leadership Team
11. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s ... June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... helping service members that have been wounded in battle and their families. Venture Construction ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology: